Prof. Dr. Joachim Mittendorf

Prof. Dr. Joachim Mittendorf is an honorary professor at the University of Leipzig and brings his expertise from Bayer Pharma AG in the field of medicinal chemistry to the Institute of Organic Chemistry.

Prof. Dr. Joachim Mittendorf

Prof. Dr. Joachim Mittendorf

Honorarprofessor

Bayer AG Pharmaceuticals, Medicinal Chemistry Wuppertal
Aprather Weg 18a
42113 Wuppertal

Telephone: +49 0 2 02 36-43 52

Curriculum Vitae

  • 1982 – 1987
    Studies and degree in Chemistry at the University of Göttingen
  • 1987 – 1989
    Ph. D. thesis with Prof. Dr. U. Schöllkopf in Organic Chemistry at the University of Göttingen supported by a Verband der Chemischen Industrie fellowship: “A Novel Ring Expansion of Dihydropyrazines and Benzodihydroaromatics“
  • 1989 – 1990
    Postdoctoral research with Prof. K.P.C. Vollhardt at the University of California, Berkeley on a Feodor-Lynen-Fellowship of the Alexander von Humboldt Foundation
  • 1990 – 1994
    Senior Scientist in Medicinal Chemistry at Bayer AG, Wuppertal; Research Areas: Antimycotics (ß-amino acids), Virology (HIV protease inhibitors)
  • 1994 – 1996
    Senior Scientist in Pharma Process Development at Bayer AG, Wuppertal: Enantiomerically pure Dihydropyridines and ß-Amino Acids
  • 1996 – 1999
    Senior Scientist in Medicinal Chemistry at Bayer AG, Wuppertal; Research Areas: CNS (neuroprotectives for the treatment of stroke, traumatic brain injury), Asthma (tryptase inhibitors), Cardiovascular Diseases (coronary heart disease, hematology)
  • 1999 – Oct 2024
    Director and since 2016 VP of Medicinal Chemistry 2 at Bayer Pharma AG, Wuppertal; responsible for heart diseases
  • 2002 – 2016
    Project leader of Bayer pharma research IT platform “Pharmacophore Informatics”
  • Since Jan 2009
    Honorarprofessor for Medicinal Chemistry, University of Leipzig, Germany
  • 2010 –  2024
    Chairmen/ deputy chairman of GDCH section Wuppertal-Hagen

  • 2015 – 2019   

    Medicinal chemistry expert in Nexavar litigation in India including several cross-examinations at Delhi High Court

  • 2020 – Oct 2024 

    Co-Chair of Drug Delivery Council at Bayer Pharmaceuticals R&D

  1. Mittendorf, J. Liebigs Ann. Chem. 1988, 1201:
    Enantioselective synthesis of (R)- and (S)- 4-methylcycloserine by the bislactim ether method.
  2. Schöllkopf, U.; Mittendorf, J. Angew. Chem. 1989, 101, 633:
    From 2,5-dihydropyrazines to 2H-1,4-diazepines, and from benzodihydroarenes to benzocycloheptene derivatives, structural variants of the antidepressant protriptylene.
  3. Hartwig, W.; Mittendorf, J. Synthesis 1991, 939:
    Enantioselective synthesis of 2,3-diamino acids by the bislactim ether method.
  4. Boese, R.; Green, J. R.; Mittendorf, J.; Mohler, D. L.; Vollhardt, K. P. C.: Angew. Chem. 1992, 104, 1643:
    The first hexabutadiynylbenzene derivative: synthesis and structure.
  5. Schmidt, U.; Schumacher, A.; Mittendorf, J.; Riedl, B. Journal of Peptide Research 1998, 52, 143:
    Contribution to the synthesis of aureobasidin A. Synthesis of cyclopeptolides containing the sequence leucyl-N-methyl- -hydroxyvalyl-(2R)-oxy-(3R)-methyl-pentanoic acid.
  6. Hartwig, W.; Mittendorf, J Encyclopedia of Reagents for Organic Synthesis 2001:
    (2S)-(+)-2,5-Dihydro-2-isopropyl-3,6-dimethoxypyrazine.
  7. Mauler, F.; Mittendorf, J.; Horváth, E.; De Vry, J. Journal of Pharmacology and Experimental Therapeutics 2002, 302, 359:
    Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4-4-4-trifluoro-1-sulfonate (BAY 37-7271) as a potent cannabinoid receptor agonist with neuroprotective properties.
  8. Steinhagen, H.; Gerisch, M.; Mittendorf, J.; Schlemmer, K.-H.; Albrecht, B. Biorg. Med. Chem. Lett. 2002, 12, 3187 :
    Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose)polymerase-1 (PARP-1).
  9. Mittendorf, J: Benet-Buchholz, J.; Fey, P. Mohrs, K.-H. Synthesis 2003, 136: 
    Efficient asymmetric synthesis of -amino acid BAY 10-8888 / PLD-118, a novel antifungal for the treatment of yeast infections.
  10. Mittendorf, J; Kunisch, F.; Matzke, M.; Militzer, H.-C.; Schmidt, A.; Schoenfeld, W. Biorg. Med. Chem. Lett. 2003, 13, 433:
    Novel antifungal -amino acids: Synthesis and activity against Candida albicans.
  11. Kuhl A; Hahn M G; Dumic M; Mittendorf J. Amino Acids 2005, 29, 89: 
    Alicyclic beta-amino acids in Medicinal Chemistry.
  12. Hasenoehrl A.; Galic T.; Ergovic G.; Marsic N.; Skerlev M.; Mittendorf J.; Geschke U.; Schmidt A.; Schoenfeld W. Antimicrobial agents and chemotherapy 2006, 50, 3011:
    In vitro activity and in vivo efficacy of icofungipen (PLD-118), a novel oral antifungal agent, against the pathogenic yeast Candida albicans.
  13. Kast R; Schirok H; Figueroa-Perez S; Mittendorf J; Gnoth M J; Apeler H; Lenz J; Franz J K; Knorr A; Hutter J; Lobell M; Zimmermann K; Munter K; Augstein K H; Ehmke H; Stasch J P British Journal of Pharmacology 2007, 152, 1070:
    Cardiovascular effects of a novel potent and highly selective azaindole-based inhibitor of Rho-kinase.
  14. Schermuly R.; Stasch J.-P.; Pullamsetti S. S.; Middendorff R.; Mueller D.; Schlüter K.-D.; Dingendorf A.; Kolosionek E.; Kaulen C.; Dumitrascu R.; Weissmann N.; Mittendorf J.; Klepetko W.; Seeger W.;, Ghofrani H. A.; Grimminger F. Eur. Respir. J. 2008, 32, 881-891:
    Expression and Function of Soluble Guanylate Cyclase in Pulmonary Arterial Hypertension.
  15. Schirok, H.; Kast, R.; Figueroa-Perez, S.; Bennabi, S.; Gnoth, M. J.; Feurer, A.; Heckroth, H.; Thutewohl, M.; Paulsen, H.; Knorr, A.; Huetter, J.; Lobell, M.; Muenter, K.; Geiss, V.; Ehmke, H.; Lang, D.; Radtke, M.; Mittendorf, J.; Stasch, J.-P. ChemMedChem 2008, 3, 1893-1904:
    Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
  16. Mittendorf, J.; Weigand S.; Alonso-Alija C.; Bischoff E.; Feurer A.; Gerisch M.; Kern A.; Knorr A.; Lang D.; Muenter K.; Radtke M.; Schirok H.; Schlemmer K.-H.; Stahl, E.; Straub A.; Wunder F.; Stasch J.-P. ChemMedChem2009, 4, 853-865.
  17. Baerfacker L.; Kuhl A.; Hillisch A.; Grosser R.; Figueroa-Pérez S.; Heckroth H.; Nitsche A.; Ergueden J.-K.; Gielen-Haertwig H.; Schlemmer K.-H.; Mittendorf, J.; Paulsen H.; Platzek J.; Kolkhof P. ChemMedChem2012, 7, 1385-1403: Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases.
  18. Griebenow N.; Schirok H.; Mittendorf J.; Straub A.; Follmann M.; Stasch J.-P.; Knorr A.; Schlemmer K.-H.; Redlich G. Biorg. Med. Chem. Lett. 2013,23, 1197-2000: Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators.
  19. Follmann M.; Griebenow N.; Hahn M. G.; Hartung J.; Mais F.-J.; Mittendorf J.; Schaefer M.; Schirok H. Stasch J.-P., Stoll F.; Straub A. Angew. Chem. Int. Ed. 2013, 52, 9442-9462: The Chemistry and Biology of Soluble Guanylate Cyclase Stimulators and Activators.
  20. Nussbaum, F.; Li, V. M.-J.; Allerheiligen, S.; Anlauf, S.; Baerfacker, L.; Bechem, M.; Delbeck, M.; Fitzgerald, M. F.; Gerisch, M.; Gielen-Haertwig, H.; Haning, H.; Karthaus, D.; Lang, D.; Lustig, K.; Meibom, D.; Mittendorf, J.; Rosentreter, U.; Schaefer, M.; Schaefer, S.; Schamberger, J.; Telan, L. A.; Tersteegen, A. ChemMedChem 2015, 10, 1163-1173: Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
  21. Nussbaum, F.; Li, V. M.-J.; Meibom D.; Anlauf, S.; Bechem M.; Delbeck, M.; Gerisch, M.;Harrenga A.;  Karthaus, D.; Lang, D.; Lustig, K.; Mittendorf, J.; Schaefer, M.; Schaefer, S.; Schamberger, J. ChemMedChem 2016, 11, 199-206: Potent and Selective Human Neutrophil Elastase Inhibitors with Novel Equatorial Ring Topology: in vivo Efficacy of the Polar Pyrimidopyridazine BAY-8040 in a Pulmonary Arterial Hypertension Rat Model
  22. Meibom D.; Albrecht-Kuepper B.; Diedrichs N.; Huebsch W.; Kast R.; Kraemer T.; Krenz U.; Lerchen H.-G.; Mittendorf J.; Nell P. G.; Suessmeier F.; Vakalopoulos A.; Zimmermann K. ChemMedChem 2017, 12, 728-737: Neladenoson Bialanate Hydrochloride: A Prodrug of a Partial Adenosine A1 Receptor Agonist for the Chronic Treatment of Heart Diseases.
  23. Follmann M.; Ackerstaff J.; Redlich G.; Wunder F.; Lang D.; Kern A.; Griebenow N.; Kroh  W.; Becker-Pelster E.-M.; Kretschmer A.; Geiss V.; Li V.; Straub A.; Mittendorf J.; Jautelat R.; Schirok H.; Schlemmer K.-H.; Lustig K.; Gerisch M.; Knorr A.; Tinel H.; Mondritzki T.; Truebel H.; Sandner P.; Stasch J.-P. J. Med. Chem.  2017, 60, 5146-5161: Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure
  24. Le Roux A.; Blaise E.; Boudreault P.-L.; Comeau C.; Doucet A.; Giarrusso M.; Collin M.-P.; Neubauer T.; Kolling F.; Goeller A.; Seep L.; Tshitenge D. T.; Wittwer M.; Kullmann M.; Hillisch A.; Mittendorf J.; Marsault E. J. Med. Chem.  2020, 63, 6774-6783:Structure-​Permeability Relationship of Semipeptidic Macrocycles-​Understanding and Optimizing Passive Permeability and Efflux Ratio

  25. Hahn, M. G.; Lampe, T.; El Sheikh, S.; Griebenow, N.; Woltering, E.; Schlemmer, K.-H.; Dietz, L.; Gerisch, M.; Wunder, F.; Becker-Pelster, E.-M.; Mondritzki, T.; Tinel, H.; Knorr, A.; Kern, A.; Lang, D.; Hueser, J.; Schomber, T.; Benardeau, A.; Eitner, F.; Truebel, H.; Mittendorf, J.; Kumar, V.; van den Akker, F.; Schaefer, M.; Geiss, V.; Sandner, P.; Stasch, J.-P. Journal of Medicinal Chemistry 2021, 64, 5323-5344: Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).

  26. Meibom, D; Meyer, J; von Buehler, C.-J.; Collins, K. D.; Maassen, S.; Gericke, K. M.; Hüser, J.; Mittendorf, J.; Ortega Hernandez, N.; Schamberger, J.; Stampfuss, J.; Straub, A.; Torge, A.; Witowski, N.; Wunder, F. Journal of Medicinal Chemistry 2023, 66, 4659-4670: BAY-6096: A Potent, Selective, and Highly Water-Soluble Adrenergic α2BAntagonist.

  27. Vakalopoulos A.; Wunder F.; Hartung I.V.; Redlich G.; Jautelat R.; Buchgraber P.; Hassfeld J.; Gromov A. V.; Lindner N.; Bierer D.; Gries J.; Kroh W.; Paulsen H.; J.; Mittendorf, Lang D.; Becker-Pelster E.; Brockschnieder D.; Geiss V.; Li V.; Straub A.; Knorr A.; Mondritzki T.; Trübel H.; Raschke M.; Schaefer M.; Thomas D.; Sandner P.; Stasch J.-P.; Follmann M.  Journal of Medicinal Chemistry 2023, 66, 7280-7303: New Generation of sGC Stimulators: Discovery of Imidazo[1,2-a]pyridine Carboxamide BAY 1165747 (BAY-747), a Long-Acting Soluble Guanylate Cyclase Stimulator for the Treatment of Resistant Hypertension.

  28. Meibom, D; Wasnaire, P; Beyer K; Broehl A; Cancho-Grande Y; Elowe N; Henninger K; Johannes K; Jungmann N; Krainz T; Lindner N; Maassen S; MacDonald B; Menshykau D; Mittendorf J; Sanchez G; Schaefer M; Stefan E; Torge A; Xing Y; Zubov D; Journal of Medicinal Chemistry 2024, 67, 2907-2940: BAY-9835: Discovery of the First Orally Bioavailable ADAMTS7 Inhibitor.

  1. Mittendorf J.; Hartwig W. Eur. Pat. Appl. 1993, EP 529469 A2: Preparation of 2,3-diamino acids from azidomethyldiketopiperazine derivatives.      
  2. Mittendorf J.; Kunisch F.; Plempel M.; Eur. Pat. Appl. 1993, EP 538691 A1: Preparation of aminotetrahydrothiophenecarboxylates as medical fungicides.   
  3. Mittendorf J.; Kunisch F.; Babczinski P.; Plempel M.; Eur. Pat. Appl. 1993, EP 538689 A1: Preparation of 3-amino-2,3-dihydro-6H-pyran-2-carboxylates as medical fungicides.   
  4. Kunisch F.; Mittendorf J,; Plempel M. Eur. Pat. Appl. 1993, EP 538688 A1: Preparation and antimycotic activity of substituted tetrahydrofurans.
  5. Kunisch F.; Mittendorf J.; Plempel M.; Militzer H.-C. Eur. Pat. Appl. 1993, EP 538692 A1: Preparation and antimycotic activity of partially known substituted pyrrolidines. 
  6. Mittendorf J.; Kunisch F.; Matzke M.; Militzer H.-C.; Endermann R.; Metzger K.; Bremm K.-D.; Plempel M.; Eur. Pat. Appl. 1993, EP 571870 A1: Preparation of 1-amino-2-carboxycyclopentanes as antimycotics and antibacterials. 
  7. Uhr H.; Kunisch F.; Wachtler M.; Kugler M.; Mittendorf J. Ger. Offen. 1995, DE 4403838 A1: Preparation of 1,3,2-benzodithiazole 1-oxides as microbicides.      
  8. Militzer, H.-C.; Matzke M.; Mittendorf J.; Schmidt A.; Ziegelbauer K.; Schoenfeld W. Ger. Offen. 1996, DE 4443890 A1: Antimicrobial cyclohex-4-enecarboxylic acids and their preparation.    
  9. Mittendorf J.; Fey P.; Junge B.; Kaulen J.; van Laak K.; Meier H.; Schohe-Loop R. Eur. Pat. Appl. 1996, EP 716081 A1: Highly selective process for the preparation of enantiomerically pure phenyl-substituted 1,4-dihydropyridine-3,5-dicarboxylic acid derivatives.   
  10. Fey P.; van Laak K.; Mittendorf J. Ger. Offen. 1996, DE 4446337 A1: Preparation of 3-cyanobenzaldehydes.   
  11. Matzke M.; Militzer H.-C.; Mittendorf J.; Kunisch F.; Schmidt A.; Schoenfeld W.; Ziegelbauer K. Eur. Pat. Appl. 1997, EP 754678 A2: Improvement of physiological tolerance of pharmaceutically active beta amino acids.   
  12. Kunisch F.; Matzke M.; Militzer H.-C.; Mittendorf J.; Babczinski P.; Schmidt A.; Schoenfeld W.; Ziegelbauer K. Ger. Offen. 1997, DE 19604225 A1: Condensation of beta amino acids and beta aminocyclohexenoic acids for use as antimicrobial agents. 
  13. Mittendorf J.; Eur. Pat. Appl. 1997, EP 805145 A1: Efficient and highly enantioselective process for the preparation of enantiomerically pure cyclopentane-beta-amino acids.  
  14. Mittendorf J.; Dressel J.; Matzke M.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Friedl A.; Horvath E.; Mauler F.; de Vry J.; Jork R. Ger. Offen. 1998, DE 19706903 A1: Use of agonists of central cannabinoid CB1 receptors in neurodegenerative diseases.   
  15. Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mohrs K.; Raddatz S.;  Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Friedl A.; Horvath E.; Mauler F.; de Vry J.; Jork R. Ger. Offen. 1998, DE 19740785 A1: Preparation of arylsulfonamides and related compounds as cannabinoid CB1 and CB2 receptor agonists.      
  16. Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mauler F.; de Vry J.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Horvath E.; Friedl A.; Ger. Offen. 2000, DE 19837627 A1: Preparation of alkylsulfonyloxyphenoxyindanylmethanol amino acid esters and related compounds as CB1 and CB2 cannabinoid receptor agonists.     
  17. Mittendorf J.; Dressel J.; Matzke M.; Keldenich J.; Mauler F.; de Vry J.; Franz J.; Spreyer, P.; Voehringer V.; Schuhmacher J.; Rock M. H.; Horvath E.; Friedl A.; Mohrs K.; Raddatz S.; Jork R. Ger. Offen. 2000, DE 19837638 A1: Preparation of aryl trifluorobutylsulfonates as CB1 receptor antagonists. 
  18. Mittendorf J.; Henning R.; Raddatz S.; Schlemmer K.-H., Hiraoka M.; Kadono H.; Mogi M.; Moriwaki T.; Murata T.; Sakakibara S.; Shimada M.; Yoshida N.; Yoshino T. PCT Int. Appl. 2000, WO2000020401 A1: Preparation of bis-benzimidazoles as tryptase inhibitors. 
  19. Haerter M.; Albrecht B.; Gerisch M.; Handke G.; Huetter J.; Jensen A.; Krahn T.; Mittendorf J.; Oehme F.; Schlemmer K.-H.; Steinhagen H. PCT Int. Appl.2002, WO2002006247 A1: Preparation of fused amidoalkyluracils as poly(ADP-ribose) synthetase inhibitors.      
  20. Feurer A.; Bennabi S.; Heckroth H.; Schirok H.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Ehmke, H. PCT Int. Appl. 2004, WO20040039796 A1: Preparation of phenylaminopyrimidines as Rho-Kinase II inhibitors for the treatment of cardiovascular diseases. 
  21. Bennabi S.; Heckroth H.; Schirok H.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Bauser M.; Feurer A.; Ehmke, H. PCT Int. Appl. 2005, WO2005058891 A1: Preparation of pyrrolopyridinyloxyphenylamides and related compounds as cardiovascular agents.  
  22. Schirok H.; Radtke M.; Mittendorf J.; Kast R.; Stasch J.-P.; Gnoth M. J.; Muenter K.; Lang D.; Figueroa Perez S.; Thutewohl M.; Bennabi S.; Ehmke, H. PCT Int. Appl. 2005, WO2005007790 A1: Preparation of heteroaryloxy-substituted phenylamino pyrimidines as Rho kinase inhibitors. 
  23. Schirok H.; Stasch J.-P.; Kast R.; Muenter K.; Gnoth M. J.; Figueroa Perez S.; Thutewohl M.; Bennabi S.; Radtke M.; Lang D.; Mittendorf J.; Ehmke, H. PCT Int. Appl. 2005, WO2005108397 A1: Preparation of substituted phenylaminopyrimidines for use as cardiovascular agents. 
  24. Schirok H.; Stasch J.-P.; Kast R.; .; Figueroa Perez S.; Muenter K.; Gnoth M. J.; Radtke M.; Lang D.; Mittendorf J. Ger. Offen. 2006, DE 102004060752 A1: Preparation of 4-phenoxy-7-azaindoles as rho kinase II inhibitors.   
  25. Schirok H.; Griebenow N.; Fuerstner C.; Mittendorf J.; Stasch J.-P.; Wunder F.; Schlemmer K.-H.; Heitmeier S.; Stoll F. PCT Int. Appl. 2007, WO2007124854 A1: Fused pyrazole derivatives as cardiovascular agents, their preparation, pharmaceutical compositions, and use in therapy. 
  26. Fuerstner C.; Schirok H.; Griebenow N.; Mittendorf J.; Stasch J.-P.; Wunder F.; PCT Int. Appl. 2007, WO2007128454 A1: Preparation of 3-tetrazolylpyrazolopyridines as cardiovascular agents.    
  27. Schirok H.; Mittendorf J.; Stasch J.-P.; Wunder F.; Stoll F.; Schlemmer K.-H. PCT Int. Appl. 2008, WO2008031513 A1: Azabicyclic derivatives as stimulators of guanylate cyclase, their preparation, pharmaceutical compositions, and use for the treatment of cardiovascular disorders.      
  28. Schirok H.; Mittendorf J.; Stasch J.-P.; Wunder F.; PCT Int. Appl. 2008, WO2008061657 A1: Preparation of imidazo[2,1-c]-1,2,4-triazoles as guanylate cyclase activators for treatment of cardiovascular diseases.   
  29. Straub A.; Suessmeier F.; Wunder F; Stasch J.-P.; Li V. M.-J.; Mittendorf J. PCT Int. Appl. 2010, WO 2010079120 A1: Preparation of fused pyrazoles and imidazoles as cardiovascular agents.
  30. Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.; Kroh W.; Knorr A.; Becker E.-M.; Wunder F.; Li V. M.-J.; Hartmann E.; Mittendorf J.; Schlemmer K.-H.; Jautelat R.; Bierer D. PCT Int. Appl. 2011, WO 2011147809 A1: Substituted 5-fluoro-1H-pyrazolopyridine derivatives as guanylate cyclase inhibitor and their preparation and use in the treatment of cardiovascular diseases.
  31. Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.;  Wunder F.; Li V. M.-J.; Mittendorf J.; Jautelat R. PCT Int. Appl. 2012, WO 2012010576 A1: Carbamate-substituted diaminopyrimidines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases.
  32. Follmann M.; Stasch J.-P.; Redlich G.; Ackerstaff J.; Griebenow N.; Knorr A.; Wunder F.; Li V. M.-J.; Mittendorf J.; Schlemmer K.-H.; Jautelat R. PCT Int. Appl. 2012, WO 2012059549 A1: Substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines as guanylate cyclase inhibitors and their preparation and use in the treatment of cardiovascular diseases.
  33. Hahn M.; Follmann M.; Huebsch W.; Becker E.-M.; Stasch J.-P.; Keldenich J.; Delbeck M.; Tinel H.; Wunder F.; Mittendorf J.; Terebesi I.; Lang D.; Martin R. PCT Int. Appl. 2014, WO 2014012934 A1: Preparation of 5-aminotetrahydroquinoline-2-carboxylic acids for use in treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

You may also like

Institute for Organic Chemistry

Read more

Faculty of Chemistry and Mineralogy

Read more

University Leipzig

Read more